. . . . . . . . . . . . "[Individuals with a CYP2C19 reduced-metabolizer genotype were estimated to have a substantial reduction in the risk of the composite primary outcome (cardiovascular death, myocardial infarction, or stroke) with prasugrel as compared with clopidogrel relative risk (RR) 0.57; 95% confidence interval (CI) 0.39-0.83.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en . . . . . "2015-02-21"^^ . . "Gene-disease associations inferred from text-mining the literature."@en . "DisGeNET evidence - LITERATURE"@en . "2015-08-25T14:38:42+02:00"^^ . . . . . . . . . . . "v3.0.0.0" . "v3.0.0" .